Literature DB >> 18484804

Strategies for dosing and switching antipsychotics for optimal clinical management.

Peter F Buckley1, Christoph U Correll.   

Abstract

Optimal clinical management of schizophrenia and bipolar disorder can be achieved through careful antipsychotic dosing and, if necessary, switching to another well-chosen antipsychotic using suitable switching strategies. For severely ill patients treated in clinical practice, adequate dosing may not result from following the relatively low dosing levels and abrupt titration schedules typically used in clinical registration trials. Data from recent effectiveness trials, naturalistic studies, and the Roadmap Expert Consensus Survey provide evidence of specific dose levels and titration schedules for antipsychotic agents that may be appropriate in clinical practice. Discontinuation and frequent switching of medication are common among patients treated with antipsychotics, but data suggest that an adequate trial of the first antipsychotic medication should be undertaken before switching to another antipsychotic medication. Making a decision to switch from a typical to an atypical antipsychotic or between atypical antipsychotics should involve consideration of variables relating to the patient, illness, medication, and the patient's environment. Switching can improve efficacy and tolerability but may also result in predictable side effects or withdrawal symptoms, including weight gain and metabolic effects as well as effects associated with prolactin changes. Many side effects that occur during switching are attributable to receptor profiles and antimuscarinic or antihistaminic blockade. Individualized switching strategies that include careful choice of medication, dose, and titration and tapering schedules; management of symptoms; and patient psychoeducation can reduce or treat side effects, increasing the likelihood of a successful switch and greater adherence and efficacy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18484804

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  20 in total

1.  The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.

Authors:  Young-Hoon Ko; Kyoung-Sae Na; Chul-Eung Kim; Seung-Hyun Kim; Yang-Whan Jeon; Jung-Seo Yi; Moon-Soo Lee; Shin-Gyeom Kim; Hyun-Ghang Jeong; Han-Yong Jung
Journal:  Psychiatry Investig       Date:  2014-10-20       Impact factor: 2.505

Review 2.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

Review 3.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

4.  The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial.

Authors:  Cenk Tek; Laura B Palmese; Andrew D Krystal; Vinod H Srihari; Pamela C DeGeorge; Erin L Reutenauer; Sinan Guloksuz
Journal:  Schizophr Res       Date:  2014-10-29       Impact factor: 4.939

5.  Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR).

Authors:  Alessandra Barraco; Andrea Rossi; Giuseppe Nicolò
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

6.  Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Authors:  Fernanda Rosa; Andreas Schreiner; Pierre Thomas; Tarek Sherif
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

7.  Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis.

Authors:  Debra L Foley; Andrew Mackinnon; Vera A Morgan; Gerald F Watts; John J McGrath; David J Castle; Anna Waterreus; Cherrie A Galletly
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

8.  Validation of a claims-based antipsychotic polypharmacy measure.

Authors:  Emily Leckman-Westin; Edith Kealey; Nitin Gupta; Qingxian Chen; Tobias Gerhard; Stephen Crystal; Mark Olfson; Molly Finnerty
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03-24       Impact factor: 2.890

9.  Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study.

Authors:  Roberto Brugnoli; Diego Novick; Josep Maria Haro; Andrea Rossi; Marco Bortolomasi; Sonia Frediani; Giuseppe Borgherini
Journal:  BMC Psychiatry       Date:  2012-07-19       Impact factor: 3.630

10.  Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.

Authors:  Joseph Peuskens; Gabriel Rubio; Andreas Schreiner
Journal:  Ann Gen Psychiatry       Date:  2014-04-01       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.